J. Xu

发表

First-line pembrolizumab (pembro) in cisplatin-ineligible patients with advanced urothelial cancer (UC): Response and survival results up to five years from the KEYNOTE-052 phase 2 study.

T. Powles, E. Plimack, D. Bajorin, 2021 .

Prevalence and co-prevalence of comorbidities among patients with type 2 diabetes mellitus

Kristy Iglay, K. Iglay, S. Engel, 2016, Current medical research and opinion.